Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 68Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 36Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 13Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Mesothelioma, Malignant 5Carcinoma 5Stomach Neoplasms 4

Interventions

fludarabine 2Paclitaxel 2Gemcitabine 2Bevacizumab 2pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Stem Cell Transplantation 1Sirolimus 1Nivolumab 1Melphalan 1Ipilimumab 1Immunoglobulin G 1Doxorubicin 1Docetaxel 1Disulfides 1Dexamethasone 1Carboplatin 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Ipilimumab × 1 year × Clear all
NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡